Lilly’s Cyramza scores in targeted lung cancer—but major competition awaits
Lilly’s Cyramza scores in targeted lung cancer—but major competition awaits
New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers
New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers
Top 10 Immuno-Oncology Startups
Top 10 Immuno-Oncology Startups
Genentech Brings Back One of Its Own as Next CEO
Genentech Brings Back One of Its Own as Next CEO
Roche wins key cancer drug approval, but taking on Merck remains a challenge
Roche wins key cancer drug approval, but taking on Merck remains a challenge
Pfizer secures 4th cancer drug approval in 2 months
Pfizer secures 4th cancer drug approval in 2 months
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
KEYTRUDA Snags Approval for Hepatocellular Carcinoma, Its 14th Approval Overall
KEYTRUDA Snags Approval for Hepatocellular Carcinoma, Its 14th Approval Overall
FDA Greenlights Another Indication for Merck’s Keytruda
FDA Greenlights Another Indication for Merck’s Keytruda
The most disputed sales outlooks in biopharma
The most disputed sales outlooks in biopharma
A timeline of key moments in the development of checkpoint inhibitors
A timeline of key moments in the development of checkpoint inhibitors
The Perils and Promise of Partnerships Between Biopharma and Data Companies
The Perils and Promise of Partnerships Between Biopharma and Data Companies
Top Pharma News of the Week
Top Pharma News of the Week
Pfizer Snags FDA Approval for New Lung Cancer Drug Vizimpro
Pfizer Snags FDA Approval for New Lung Cancer Drug Vizimpro
Top News from the IASLC 19th World Conference on Lung Cancer 2018
Top News from the IASLC 19th World Conference on Lung Cancer 2018
Tecentriq sets the bar in small-cell lung cancer
Tecentriq sets the bar in small-cell lung cancer
